Aura Biosciences
Focus: Aura Biosciences is a Boston-based oncology-focused biotech specializing in pseudo-virus delivery technology for ocular and systemic cancers. The company is in active clinical development with a lead candidate in Phase 3 for choroidal melanoma.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Open Jobs
6
Should You Work at Aura Biosciences?
AI assessmentAura offers meaningful early-stage impact in a specialized oncology niche, but recent layoffs and limited hiring signal near-term uncertainty—best for risk-tolerant professionals seeking deep technical ownership.
Why Work Here
- Lead program (belzupacap sarotalocan) is in Phase 3 for choroidal melanoma with regulatory momentum
- Proprietary pseudo-virus delivery platform offers differentiated technology and IP protection in oncology
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Registry Study
Choroidal MelanomaA Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Choroidal MelanomaClinical Trials (1)
Help build intelligence for Aura Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.